Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone propionate - inhalation suspension for nebulisation - fluticasone propionate 2 mg / 2 ml - fluticasone - fluticasone - in adults and adolescents over 16 years flixotide nebules can be used:for prophylactic management of severe chronic asthma in patients requiring high dose inhaled or oral corticosteroid therapy. it reduces symptoms and exacerbations of asthma in patients previously treated with other prophylactic therapy.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - pneumococcal polysaccharide serotype 1; pneumococcal polysaccharide serotype 14; pneumococcal polysaccharide serotype 18c; pneumococcal polysaccharide serotype 19 f; pneumococcal polysaccharide serotype 23f; pneumococcal polysaccharide serotype 4; pneumococcal polysaccharide serotype 5; pneumococcal polysaccharide serotype 6b; pneumococcal polysaccharide serotype 7f; pneumococcal polysaccharide serotype 9v - suspension for injection - pneumococcal polysaccharide serotype 19 f 3 mcg / 0.5 ml; pneumococcal polysaccharide serotype 1 1 mcg / 0.5 ml; pneumococcal polysaccharide serotype 4 3 mcg / 0.5 ml; pneumococcal polysaccharide serotype 5 1 mcg / 0.5 ml; pneumococcal polysaccharide serotype 6b 1 mcg / 0.5 ml; pneumococcal polysaccharide serotype 7f 1 mcg / 0.5 ml; pneumococcal polysaccharide serotype 9v 1 mcg / 0.5 ml; pneumococcal polysaccharide serotype 14 1 mcg / 0.5 ml; pneumococcal polysaccharide serotype 18c 3 mcg / 0.5 ml; pneumococcal polysaccharide serotype 23f 1 mcg / 0.5 ml - pneumococcus, purified polysaccharides antigen conjugated - pneumococcus, purified polysaccharides antigen conjugated - active immunisation against invasive disease, pneumonia and acute otitis media caused by streptococcus pneumoniae serotypes 1, 4, 5, 6b, 7f, 9v, 14, 18c, 19f, and 23f in infants and children from 6 weeks up to 5 years of age.the use of synflorix should be determined on the basis of official recommendations taking into consideration the impact on pneumococcal diseases in different age groups as well as the variability of the epidemiology in different geographical areas.10.07.2017 בקשה לשינוי משטר מינוןthree-dose primary seriesthe recommended immunisation series to ensure optimal protection consists of four doses, each of 0.5 ml. the primary infant series consists of three doses with the first dose usually given at 2 months of age and with an interval of at least 1 month between doses. the first dose may be given as early as six 6 weeks of age. a booster (fourth) dose is recommended at least 6 months after the last priming primary dose and may be given from the age of 9 months onwards (preferably between 12 and

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - diphtheria toxoid; filamentous haemagglutinin (fha); pertactin; pertussis toxoid (pt); tetanus toxoid - suspension for injection - diphtheria toxoid nlt 30 iu; tetanus toxoid nlt 40 iu; pertactin 8 mcg / 0.5 ml; filamentous haemagglutinin (fha) 25 mcg / 0.5 ml; pertussis toxoid (pt) 25 mcg / 0.5 ml - bacterial and viral vaccines, combined - infanrix is indicated as a booster dose for children 15 months to 7 years of age who have previously been immunised with three or four doses of either dtpa vaccine or diphtheria, tetanus and whole-cell pertussis (dtpw) vaccine. active primary immunisation against diphteria, tetanus and pertussis from the age 2 months onward.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - albendazole - tablets - albendazole 400 mg - albendazole - albendazole - albendazole is indicated for the treatment of the following systemic helminth diseases: * echinococcosis (hydatid disease)albendazole is indicated for the treatment of liver, lung and peritoneal cysts. experience with bone cysts and those in the central nervous system and heart is limited. * cystic echinococcosis (caused by echinococcus granulosus)albendazole is used in patients with cystic echinococcosis:1. when surgical intervention is not feasible .2. as a co-adjunct to surgical treatment. 3. prior to surgical intervention. 4. if preoperative treatment was too short, if spillage has occurred or if viable cysts were found at surgery. 5. following percutaneous drainage of cysts for diagnostic or therapeutic reasons. * alveolar echinococcosis (caused by echinococcus multilocularis)although its efficacy has not been completely demonstrated in clinical trials, albendazole is used in patients with alveolar echinococcosis in the following situations:1. in inoperable disease, particularly in cases of local or distant metastasis.2. following palliative surgery.3. following radical surgery or liver transplantation.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - salbutamol as sulfate - powder for inhalation - salbutamol as sulfate 200 mcg/dose - salbutamol - salbutamol - relief of bronchospasm in broncial asthma of all types, chronic, bronchitis and emphysema.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - clobetasol propionate - solution - external - clobetasol propionate 0.05 %w/w - clobetasol - clobetasol - for the topical treatment of inflammatory conditions of the scalp responsive only to corticosteroids.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - lamivudine - solution (oral) - lamivudine 5 mg/ml - lamivudine - lamivudine - zeffix is indicated for the treatment of chronic hepatitis b associated with the evidence of hepatitis b viral (hbv) replication and active liver inflammation in adults and also in children and adolescents aged 2 to 17 years old.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - purified hepatitis b antigen - suspension for injection - purified hepatitis b antigen 20 mcg / 1 ml - hepatitis b, purified antigen - hepatitis b, purified antigen - engerix b is indicated for active immunisation against hepatitis b virus infection (hbv) caused by all known subtypes in non immune subjects .. the 20 µg dose vaccine in 1.0 ml suspension is intended for use in subjects 16 years of age and above. the 10 µg dose vaccine in 0.5 ml suspension is intended for use in subjects up to and including 15 years of age, including neonates. the categories within the population to be immunised are determined on the basis of official recommendations.it can be expected that hepatitis d will also be prevented by immunisation with engerix b as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - purified hepatitis b antigen - suspension for injection - purified hepatitis b antigen 10 mcg / 0.5 ml - hepatitis b, purified antigen - hepatitis b, purified antigen - engerix b is indicated for active immunisation against hepatitis b virus infection (hbv) caused by all known subtypes in non immune subjects . the 20 µg dose vaccine in 1.0 ml suspension is intended for use in subjects 16 years of age and above. the 10 µg dose vaccine in 0.5 ml suspension is intended for use in subjects up to and including 15 years of age, including neonates. the categories within the population to be immunised are determined on the basis of official recommendations.it can be expected that hepatitis d will also be prevented by immunisation with engerix b as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - diphtheria toxoid; filamentous haemagglutinin (fha); haemophilus b; hepatitis b vaccines; pertactin; pertussis toxoid (pt); poliovirus type 1 inactivated; poliovirus type 2 inactivated; poliovirus type 3 inactivated; tetanus toxoid - powder and suspension for suspension for injection - filamentous haemagglutinin (fha) 25 mcg/dose; diphtheria toxoid nlt 30 iu/dose; tetanus toxoid nlt 40 iu/dose; hepatitis b vaccines 10 mcg/dose; poliovirus type 1 inactivated 40 du/dose; poliovirus type 2 inactivated 8 du/dose; poliovirus type 3 inactivated 32 du/dose; haemophilus b 10 mcg/dose; pertactin 8 mcg/dose; pertussis toxoid (pt) 25 mcg/dose - bacterial and viral vaccines, combined - infantix hexa is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and disease caused by haemophilus influenza type b for infants between 6 weeks and 36 months of age.